Drug Profile
Research programme: VLA-4 integrin antagonists - Ajinomoto
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ajinomoto
- Class
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Japan
- 10 Apr 2007 Preclinical trials in Inflammation in Japan (unspecified route)